Core Insights - The company, Shanghai Junshi Biosciences Co., Ltd. (复宏汉霖), has experienced rapid growth in its overseas business, with multiple products approved for sale in Europe and the United States [1] - The company has established a comprehensive integrated system for research, registration, and production, enabling it to continuously deliver innovative assets globally [1] Group 1 - The company has 10 products approved in over 60 markets worldwide [2] - The research pipeline includes over 50 early-stage molecules, with approximately 70% focused on best-in-class (BIC) and 15% on first-in-class (FIC) [2] - The global clinical team consists of nearly 600 members, covering over 1,000 research centers across more than 20 countries [2] Group 2 - The company has completed over 1,150 batches of commercial production that meet international GMP standards [2] - A commercial team of about 1,600 people has been established in China, with over 20 partnerships for commercialization overseas [2] - The company plans to launch over 20 products globally by 2030, with more than 15 expected to be approved in the U.S. and Europe [3] Group 3 - Future innovations will focus on ADCs, multi-antibodies, and TCEs across various disease areas, including oncology, autoimmune diseases, metabolism, and central nervous system disorders [3] - The company's enhanced global commercialization capabilities are expected to drive further growth in overseas revenue, solidifying its position as an international biopharmaceutical company [3]
复宏汉霖CEO朱俊：已具备向全球持续输出创新资产的系统能力